DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Hexabrix (Ioxaglate Meglumine / Ioxaglate Sodium) - Side Effects and Adverse Reactions

 
 



ADVERSE REACTIONS

General

Adverse reactions to injectable contrast media fall into two categories: chemotoxic reactions and idiosyncratic reactions.

Chemotoxic reactions result from the physio-chemical properties of the contrast media, the dose and the speed of injection. All hemodynamic disturbances and injuries to organs or vessels perfused by the contrast medium are included in this category.

Idiosyncratic reactions include all other reactions. They occur more frequently in patients 20 to 40 years old. Idiosyncratic reactions may or may not be dependent on the dose injected, the speed of injection, the mode of injection and the radiographic procedure. Idiosyncratic reactions are subdivided into minor, intermediate and severe. The minor reactions are self-limited and of short duration; the severe reactions are life-threatening and treatment is urgent and mandatory.

NOTE: Not all of the following adverse reactions have been reported with HEXABRIX. Because HEXABRIX is an iodinated intravascular contrast agent, all of the side effects and toxicity associated with agents of this class are theoretically possible, and this should be borne in mind when HEXABRIX is administered.

Severe, life-threatening anaphylactoid reactions, mostly of cardiovascular origin, have occurred following the administration of HEXABRIX as well as other iodine-containing contrast agents. Most deaths occur during injection or 5 to 10 minutes later; the main feature being cardiac arrest with cardiovascular disease as the main aggravating factor. Isolated reports of hypotensive collapse and shock are found in the literature. Based upon clinical literature, reported deaths from the administration of conventional iodinated contrast agents range from 6.6 per 1 million (0.00066 percent) to 1 in 10,000 patients (0.01 percent).

Regardless of the contrast agent employed, the overall estimated incidence of serious adverse reactions is higher with coronary arteriography than with other procedures. Cardiac decompensation, serious arrhythmias, or myocardial ischemia or infarction may occur during coronary arteriography and left ventriculography.

The most frequent adverse reactions are nausea, vomiting, facial flush and a feeling of body warmth. These are usually of brief duration. In double-blind clinical trials, HEXABRIX produced less discomfort upon injection (pain and heat) when compared to various other contrast agents. Other reactions include the following:

Hypersensitivity reactions: Dermal manifestations of urticaria with or without pruritus, erythema and maculopapular rash. Dry mouth. Sweating. Conjunctival symptoms. Facial, peripheral and angioneurotic edema. Symptoms related to the respiratory system include sneezing, nasal stuffiness, coughing, choking, dyspnea, chest tightness and wheezing, which may be initial manifestation of more severe and infrequent reactions including asthmatic attack, laryngospasm and bronchospasm with or without edema, pulmonary edema, apnea and cyanosis. Rarely, these allergic-type reactions can progress into anaphylaxis with loss of consciousness, coma, severe cardiovascular disturbances, and death.

Cardiovascular reactions: Generalized vasodilation, flushing and venospasm. Occasionally, thrombosis or rarely, thrombophlebitis. Extremely rare cases of disseminated intravascular coagulation resulting in death have been reported. Severe cardiovascular responses include rare cases of hypotensive shock, coronary insufficiency, cardiac arrhythmia, fibrillation and arrest. These severe reactions are usually reversible with prompt and appropriate management; however, fatalities have occurred.

Technique reactions: Extravasation with burning pain, hematomas, ecchymosis and tissue necrosis, vascular constriction due to injection rate, thrombosis and thrombophlebitis.

Neurological reactions: Spasm, convulsions, aphasia, syncope, paresis, paralysis resulting from spinal cord injury and pathology associated with the syndrome of transverse myelitis, visual field losses which are usually transient but may be permanent, coma and death.

Other reactions: Headache, trembling, shaking, chills without fever, hyperthermia and lightheadedness. Temporary renal shutdown or other nephropathy.

(Adverse reactions to specific procedures receive comment under that procedure.)



REPORTS OF SUSPECTED HEXABRIX SIDE EFFECTS / ADVERSE REACTIONS

Below is a sample of reports where side effects / adverse reactions may be related to Hexabrix. The information is not vetted and should not be considered as verified clinical evidence.

Possible Hexabrix side effects / adverse reactions in 78 year old female

Reported by a individual with unspecified qualification from Brazil on 2011-11-09

Patient: 78 year old female

Reactions: Anaphylactic Reaction, Distributive Shock

Adverse event resulted in: life threatening event, hospitalization

Suspect drug(s):
Hexabrix



Possible Hexabrix side effects / adverse reactions in 86 year old female

Reported by a individual with unspecified qualification from Brazil on 2011-11-10

Patient: 86 year old female

Reactions: Flushing, Respiratory Rate Increased, Pruritus, Dyspnoea, Oedema

Adverse event resulted in: life threatening event

Suspect drug(s):
Hexabrix
    Dosage: intravenous (not otherwise specified)
    Indication: Abdomen Scan
    Start date: 2011-10-17
    End date: 2011-10-17

Hexabrix
    Dosage: intravenous (not otherwise specified)
    Indication: Arteriogram Coronary
    Start date: 2011-10-17
    End date: 2011-10-17

Hexabrix
    Dosage: intravenous (not otherwise specified)
    Indication: Catheterisation Cardiac
    Start date: 2011-10-17
    End date: 2011-10-17

Hexabrix
    Dosage: intravenous (not otherwise specified)
    Indication: Arteriogram Renal
    Start date: 2011-10-17
    End date: 2011-10-17



Possible Hexabrix side effects / adverse reactions in 76 year old male

Reported by a health professional (non-physician/pharmacist) from Japan on 2011-12-14

Patient: 76 year old male

Reactions: Platelet Count Decreased, Shock

Adverse event resulted in: life threatening event

Suspect drug(s):
Hexabrix



See index of all Hexabrix side effect reports >>

Drug label data at the top of this Page last updated: 2007-11-20

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012